Dashboard
Manage Tickers

ALT


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

altimmune-corrects-previous-release-says-reduction-of-visceral-adipose-tissue-vat-at-week-48-adjusted-to-283-from-256-and-subcutaneous-adipose-tissue-reduction-revised-to-195-from-201
Altimmune Corrects Previous Release; Says ...
09/10/2024 17:14:09

https://www.globenewswire.com/news-release/2024/09/10/2943994/0/en/CORRECTION-Altimmune-Presents-Results-of-a-Phase-2-MRI-Based...

altimmune-presents-data-from-its-phase-2-mri-based-body-composition-sub-study-of-pemvidutide-in-subjects-with-overweight-and-obesity
Altimmune Presents Data From Its Phase 2, ...
09/10/2024 11:52:31

In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 wee...

decoding-4-analyst-evaluations-for-altimmune
Decoding 4 Analyst Evaluations For Altimmune
08/22/2024 18:00:17

hc-wainwright--co-reiterates-buy-on-altimmune-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Alti...
08/22/2024 17:40:26

HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.

b-riley-securities-reiterates-buy-on-altimmune-maintains-20-price-target
B. Riley Securities Reiterates Buy on Alti...
08/12/2024 18:44:47

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $20 price target.

correction-altimmune-q2-2024-gaap-eps-035-misses-034-estimate-sales-5000k-down-from-6000k-yoy
CORRECTION: Altimmune Q2 2024 GAAP EPS $(0...
08/08/2024 11:23:27

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by...

watching-altimmune-traders-circulate-new-york-post-article-new-weight-loss-drug-may-be-better-than-ozempic--heres-how
Watching Altimmune; Traders Circulate New ...
06/27/2024 14:26:48

https://nypost.com/2024/06/27/lifestyle/weight-loss-drug-pemvidutide-may-be-better-than-ozempic-trial/

why-are-altimmune-shares-trading-lower-wednesday
Why Are Altimmune Shares Trading Lower Wed...
06/26/2024 20:18:34

Altimmune shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, the compan...

altimmune-announces-passing-of-chief-financial-officer-richard-eisenstadt-eisenstadts-duties-are-being-assumed-and-performed-bt-finance-and-accounting-team-until-replacement-is-named
Altimmune Announces Passing Of Chief Finan...
06/26/2024 11:34:13

b-riley-securities-reiterates-buy-on-altimmune-maintains-20-price-target
B. Riley Securities Reiterates Buy on Alti...
06/25/2024 14:03:33

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $20 price target.

altimmune-stock-is-rising-monday-whats-driving-the-action
Altimmune Stock Is Rising Monday: What's D...
06/24/2024 13:16:57

Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a re...

Core News & Articles
Market-Moving News for June 24th
06/24/2024 12:39:04

ALNY: 14% | Alnylam Pharmaceuticals shares are trading higher after the company announced topline results from its HELIOS-B Pha...

rxo-alnylam-pharmaceuticals-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
RXO, Alnylam Pharmaceuticals And Other Big...
06/24/2024 11:54:53

altimmune-presents-data-sunday-from-phase-2-momentum-trial-of-pemvidutide-in-obesity-during-oral-presentation-at-american-diabetes-associations-84th-scientific-sessions
Altimmune Presents Data Sunday From Phase ...
06/23/2024 18:50:28

Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTU...

forecasting-the-future-5-analyst-projections-for-altimmune
Forecasting The Future: 5 Analyst Projecti...
06/21/2024 18:01:12

piper-sandler-maintains-overweight-on-altimmune-maintains-25-price-target
Piper Sandler Maintains Overweight on Alti...
06/21/2024 17:51:37

Piper Sandler analyst Yasmeen Rahimi maintains Altimmune (NASDAQ:ALT) with a Overweight and maintains $25 price target.

altimmune-presents-new-data-on-pemvidutides-benefits-for-liver-disease-and-obesity-at-easl-congress
Altimmune Presents New Data on Pemvidutide...
06/05/2024 11:12:26

Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflam...

how-is-the-market-feeling-about-altimmune
How Is The Market Feeling About Altimmune?
06/03/2024 13:00:20

hc-wainwright--co-reiterates-buy-on-altimmune-maintains-12-price-target
HC Wainwright & Co. Reiterates Buy on Alti...
05/14/2024 11:51:33

HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.

jmp-securities-maintains-market-outperform-on-altimmune-lowers-price-target-to-24
JMP Securities Maintains Market Outperform...
05/10/2024 16:34:39

JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price targ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION